menu
    • menu
    [{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Macromoltek","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"CytoImmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Isleworth Healthcare Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"TF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Cytovia Therapeutics \/ TF Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ TF Capital"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0.82999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.82999999999999996,"dosageForm":"Infusion","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cytovia Therapeutics","amount2":0.82999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.82999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cytovia Therapeutics","amount2":0.82999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.82999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"CytoLynx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CYT-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ CytoLynx","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ CytoLynx"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CYT-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-338","moa":"CD-38","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-338","moa":"CD-38","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CYT-150","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0.78000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Cytovia Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Cytovia Therapeutics

    Menu

    Cytovia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Cellectis

                            Deal Size : $825.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeut...

                            Details : Under the partnership, Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC-derived NK Cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candid...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $20.0 million

                            January 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Cellectis

                            Deal Size : $825.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-338

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics To Present New Data on CD38 Flex-NK™ Cell Engager Bispecific Antibodies for Multiple My...

                            Details : CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activation receptor NKp46.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : CYT-338

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-338

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics Presents Antitumor Activity of Its Cd38-targeting FLEX-NK™ Cell Engager Antibody at EHA...

                            Details : CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : CYT-338

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303,iNK Cell

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK™ Cell Engag...

                            Details : First in vivo data demonstrated anti-tumor activity of Glypican-3 (GPC3) Flex-NK™ cell engager CYT-303 in combination with iNK cells in an animal model of Hepatocellular carcinoma (HCC).

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : CYT-303,iNK Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Cellectis

                            Deal Size : $825.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therape...

                            Details : Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer i...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $20.0 million

                            April 27, 2022

                            Lead Product(s) : CYT-303,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Cellectis

                            Deal Size : $825.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Isleworth Healthcare Acquisition Corp.

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to...

                            Details : In addition, CYT-503, a GPC3-targeting CAR-iNK cell therapeutic, is designed to improve specificity for tumor targeting. Cytovia expects to file INDs for CYT-303 and CYT-100, followed by INDs for CYT-150 and CYT-503.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : CYT-303,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Isleworth Healthcare Acquisition Corp.

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK Engager Multispecific A...

                            Details : CYT 303 is a FLEX-NK® tetravalent bispecific trifunctional antibody targeting GPC3, a glycoprotein highly expressed on solid tumors, including Hepatocellular carcinoma, but not on adult healthy cells, is being developed to treat solid tumors expressing ...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 16, 2022

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Cellectis

                            Deal Size : $825.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in Chin...

                            Details : Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field, including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer i...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Cellectis

                            Deal Size : $825.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : TF Capital

                            Deal Size : $45.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK...

                            Details : TF Capital, a leading China-based biotech institutional investor and Cytovia have formed CytoLynx Therapeutics, and invests to finance the IND enabling and initial clinical development of the pipeline programs including CYT-303.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 13, 2021

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : TF Capital

                            Deal Size : $45.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cytovia Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-100

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : CytoLynx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture to Advance NK Cell Therapy Pipe...

                            Details : CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization including CYT-100.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $400.0 million

                            September 13, 2021

                            Lead Product(s) : CYT-100

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : CytoLynx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth